Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes
Article
Published on
Journal: Multiple sclerosis and related disorders
[Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료기술,
Journal: Multiple sclerosis and related disorders
[Category] COVID19(2023년), SARS, 바이오마커, 진단, 치료기술,
[키워드] administration
age
anti-CD20
anti-CD20 therapy
Anti-SARS-CoV-2 S
antibody
Antibody Response
Antibody titer
appear
B-cell
CD20
cell count
Clinical outcome
Cohort
collected
Comprehensive
COVID-19
COVID-19 infection
COVID-19 vaccination
death
demographic
demonstrated
diagnosed with COVID-19
died
disease
Disease modifying therapy
effective
enrolled
female
FIVE
Follow-up
healthy control
healthy controls
humoral
Humoral immunity
Humoral response
ICU care
Immune profile
immunoglobulins
incidence
increased risk
investigation
less
longitudinal
Lymphocyte count
Multiple
multiple sclerosis
outcome
Patient
preventing infection
profile
reduced
required
Responder
response to vaccination
Result
retrospective
SARS-CoV-2 spike
sclerosis
serum
severe disease
significantly lower
single-center study
therapy
Treatment
vaccinated against COVID-19
vaccination
Vaccine
[DOI] 10.1016/j.msard.2022.104079 [Article Type] Article
[DOI] 10.1016/j.msard.2022.104079 [Article Type] Article